欧洲中心复发难治侵袭性B细胞淋巴瘤商业抗CD19 CAR-T治疗的真实世界研究
该回顾性研究纳入2018年1月至2019年11月在本机构接受商业抗CD19 CAR-T细胞(阿基仑赛和替沙仑赛)采集的70例复发难治侵袭性B细胞淋巴瘤患者,其中61例回输。中位随访5.7个月,中位无进展生存期3.0个月,中位总生存期11.8个月;细胞因子释放综合征任何级别发生率为85%,免疫效应细胞相关神经毒性综合征任何级别发生率为28%。
要点
- 回输后1个月和3个月总缓解率分别为63%和45%,完全缓解率分别为48%和39%。
- 多因素分析显示,CAR-T前治疗线数≥4线(P=0.010)和淋巴细胞清除时C反应蛋白>30 mg/L(P<0.001)与较差的无进展生存期相关。
- 仅C反应蛋白>30 mg/L与较短的总生存期相关(P=0.009)。
核心结论
- 本分析描述了欧洲规模最大的阿基仑赛和替沙仑赛治疗复发难治侵袭性B细胞淋巴瘤的真实世界队列之一。
研究设计与样本
- 回顾性研究,收集2018年1月至2019年11月在本机构接受商业CAR-T细胞采集的70例患者数据,其中61例回输。
- 回输时中位年龄59岁(范围27-75岁),既往治疗中位线数为3线(范围2-6线)。
主要发现
- 回输后1个月和3个月总缓解率分别为63%和45%,完全缓解率分别为48%和39%。
- 中位随访5.7个月,中位无进展生存期为3.0个月(95%CI 2.8-8.8个月),中位总生存期为11.8个月(95%CI 6.0-12.6个月)。
- 多因素分析中,与较差无进展生存期相关的因素为CAR-T前既往治疗线数≥4线(P=0.010)和淋巴细胞清除时C反应蛋白>30 mg/L(P<0.001)。
- 与较短总生存期相关的唯一因素为C反应蛋白>30 mg/L(P=0.009)。
- 任何级别细胞因子释放综合征发生率为85%,其中≥3级为8%;任何级别免疫效应细胞相关神经毒性综合征发生率为28%,其中≥3级为10%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of use, efficacy and safety for axi-cel and tisa-cel. Data from 70 patients who underwent apheresis for commercial CAR T cells between January 2018 and November 2019 in our institution were retrospectively collected. Sixty-one patients were infused. The median age at infusion was 59 years old (range 27-75 years). The median number of prior therapies was 3 (range, 2-6). The overall response rates (ORRs) at 1 month and 3 months were 63% and 45%, respectively, with 48% and 39% achieving a complete response (CR), respectively. After a median follow-up after infusion of 5.7 months, the median progression-free survival (PFS) was 3.0 months (95% CI, 2.8-8.8 months), and the median overall survival (OS) was 11.8 months (95% CI, 6.0-12.6 months). In multivariate analysis, factors associated with poor PFS were the number of previous lines of treatment before CAR T cells (≥4) (P = .010) and a C reactive protein (CRP) value >30 mg/L at the time of lymphodepletion (P < .001). Likewise, the only factor associated with a shorter OS was CRP >30 mg/L (P = .009). Cytokine release syndrome (CRS) of any grade occurred in 85% of patients, including 8% of patients with CRS of grade 3 or higher. Immune cell-associated neurotoxicity syndrome (ICANS) of any grade occurred in 28% of patients, including 10% of patients with ICANS of grade 3 or higher. Regarding efficacy and safety, no significant difference was found between axi-cel and tisa-cel. This analysis describes one of the largest real-life cohorts of patients treated with axi-cel and tisa-cel for R/R aggressive B cell lymphoma in Europe.
引用
- Sesques P, Ferrant E, Safar V, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020. PMID: 32744738. doi:10.1002/ajh.25951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。